XNAS · DTIL

+2.88% · +$0.1800 · Vol 332.5K

Market closed · last close 4:00 PM ET · price as of 16:01:32 ET

Precision BioSciences, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

$6.43

Card

Relationship Map

Follow $DTIL

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $DTIL by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measured

Thu Oct 8 · last completed session · Markets closed · resumes Fri 9:30 ET · DTIL

Methodology

DTIL

Precision BioSciences, Inc. Common Stock

Thu Oct 8 · last completed session · Markets closed · resumes Fri 9:30 ET

62/100

Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100

Veridion Score

Upper range · MEDIUM confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 8 · last completed session · Markets closed · resumes Fri 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is DTIL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move DTIL next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Coverage building

No dated catalysts found for DTIL in the current source window. The page stays empty rather than inventing an event without a receipt.

About Precision BioSciences, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2019

Employees

Country

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$6.25

Day high

$6.53

Day low

$6.19

Previous close

$6.25

52W high

$9.28

-30.71% from high

52W low

$3.57

50% of range

Market cap

$172.5M

Beta

0.60

Shares out

27.6M

Volume

332.5K

1.33× rel vol

Avg volume

249.6K

VWAP

$6.41

Price history computed in-house

+1.90%

-11.31%

-26.60%

+9.35%

YTD

+54.57%

SMA 50 $7.21 · below

SMA 200 $6.35 · above

52W position 50%

DTIL overview

Veridion Score

Registered · 2026-10-08

6 of 6 factors measured

Latest receipt rows

No recent disclosure on file.

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around DTIL.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

DTIL insider activity

Precision BioSciences, Inc. Common Stock

90 days, by filing date. Snapshot time unavailable.

Score

Not evaluated

Pressure

Not evaluated

Transactions

Unavailable

Filings

Unavailable

Buys / sells

Unavailable

Net value

Not evaluated

Insiders

Unavailable

Cluster

Not evaluated: the receipt-backed Form 4 snapshot could not be read

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

Form 4 evidence state

Not evaluated: the receipt-backed Form 4 snapshot could not be read.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in DTIL

Congress tracker Open ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

DTIL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for DTIL in this window.

Lobbying spend

DTIL lobbying filings, year to date.

Registered lobbying filings matched to Precision BioSciences, Inc. Common Stock.

Not disclosed

Refresh interval: 12hSource: LDA disclosure filings

No lobbying filings on file for DTIL in this window.

Analyst ratings

Sovereign unlock shows live analyst consensus for DTIL.

Options

Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Methodology

No related ticker met the data requirements for this rail.

Follow $DTIL

Why is DTIL moving today?

What can move DTIL next.

DTIL overview

Related filings and maps

DTIL insider activity

DTIL contract awards, year to date.

DTIL lobbying filings, year to date.

Cross-references from this score page.

What can move DTIL next.

DTIL insider activity

Cross-references from this score page.